Literature DB >> 2688031

Cancer-induced immunosuppression: implications for therapy?

R E Pollock1, J A Roth.   

Abstract

Cancer-induced immunosuppression can be caused by a variety of effects. These include factors produced by the host in response to the presence of tumor or factors elaborated by the tumor itself. Disseminated tumor can lead to host debility with associated anergy. Some immunosuppressive effects are due to the manner in which the host processes (or fails to process) the tumor as an antigenic stimulus. Lastly, antitumor treatments can have a detrimental impact on host antitumor immunity. Recent research findings from our laboratories implicate surgical stress effects and tumor-mediated production of growth factors such as transforming growth factor beta (TGF-beta) as being important causes of host immune impairment. An accurate understanding of the mechanisms underlying host antitumor immune impairment will be critical in the successful development of immunotherapy strategies for use in the surgical oncology patient.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2688031     DOI: 10.1002/ssu.2980050607

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  17 in total

1.  Clinical outcomes according to primary treatment in gastric cancer patients with peritoneal seeding.

Authors:  Jung Min Bae; Kyoung Joon Yeo; Se Won Kim; Sang Woon Kim; Sun Kyo Song
Journal:  J Gastric Cancer       Date:  2011-09-29       Impact factor: 3.720

2.  The clinical value of non-curative resection followed by chemotherapy for incurable gastric cancer.

Authors:  Kyung Jai Ko; Jung Ho Shim; Han Mo Yoo; Seong Il O; Hae Myung Jeon; Cho Hyun Park; Dong Jin Jeon; Kyo Young Song
Journal:  World J Surg       Date:  2012-08       Impact factor: 3.352

3.  [Significance of palliative resection of gastrointestinal tumors].

Authors:  S Beller; P M Schlag
Journal:  Chirurg       Date:  2006-03       Impact factor: 0.955

4.  Is there a role for palliative gastrectomy in patients with stage IV gastric cancer?

Authors:  Reza F Saidi; Stephen G ReMine; Paul S Dudrick; Nader N Hanna
Journal:  World J Surg       Date:  2006-01       Impact factor: 3.352

5.  Survival benefit of non-curative gastrectomy for gastric cancer patients with synchronous distant metastasis.

Authors:  Chen Li; Min Yan; Jun Chen; Min Xiang; Zheng Gang Zhu; Hao Ran Yin; Yan Zheng Lin
Journal:  J Gastrointest Surg       Date:  2009-11-25       Impact factor: 3.452

6.  Recurrent GI Bleeding and Surgery Following the Initial Response to Imatinib Therapy in GIST of the Stomach.

Authors:  Ihab I El Hajj; Aref Chehal; Nagi S El Saghir
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

7.  The result of conversion surgery in gastric cancer patients with peritoneal seeding.

Authors:  Se Won Kim
Journal:  J Gastric Cancer       Date:  2014-12-26       Impact factor: 3.720

8.  Role of metastasectomy on overall survival of patients with metastatic gastric cancer.

Authors:  Seung Wook Yang; Min Gyu Kim; Ju Hee Lee; Sung Joon Kwon
Journal:  J Gastric Cancer       Date:  2013-12-31       Impact factor: 3.720

Review 9.  Clinical modalities for management of gastric cancer hepatic metastasis.

Authors:  Feng Tao; Jieqing Lv; Wei Wang; Ketao Jin
Journal:  Int J Clin Exp Med       Date:  2015-11-15

10.  The value of resection of primary tumor in gastric cancer patients with liver metastasis.

Authors:  Sevim Turanli
Journal:  Indian J Surg       Date:  2010-08-26       Impact factor: 0.656

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.